Otsuka Pharmaceutical agreed to acquire Transcend Therapeutics for $1.22 billion to advance a neuroplastogen approach in posttraumatic stress disorder (PTSD). Transcend’s lead asset, TSND-201, is an oral neuroplastogen that has begun patient recruitment for a Phase 3 trial in the U.S., following development plans for PTSD and major depressive disorder. The deal gives Otsuka access to a mechanistically differentiated pipeline built around neuroplasticity modulation, with TSND-201 acting via monoamine transporter pathways. Otsuka is framing the acquisition as a way to expand its psychiatry and neuroscience capabilities and work closely with regulators on late-stage development. For the broader biotech market, the transaction underscores continued pharma appetite for neuropsychiatric assets with clear clinical progression and oral administration advantages.